Cargando…
Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens
Detecting the entire repertoire of tumor-specific reactive tumor-infiltrating lymphocytes (TILs) is essential for investigating their immunological functions in the tumor microenvironment. Current in vitro assays identifying tumor-specific functional activation measure the upregulation of surface mo...
Autores principales: | Draghi, Arianna, Chamberlain, Christopher Aled, Khan, Shawez, Papp, Krisztian, Lauss, Martin, Soraggi, Samuele, Radic, Haja Dominike, Presti, Mario, Harbst, Katja, Gokuldass, Aishwarya, Kverneland, Anders, Nielsen, Morten, Westergaard, Marie Christine Wulff, Andersen, Mads Hald, Csabai, Istvan, Jönsson, Göran, Szallasi, Zoltan, Svane, Inge Marie, Donia, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543011/ https://www.ncbi.nlm.nih.gov/pubmed/34707600 http://dx.doi.org/10.3389/fimmu.2021.705422 |
Ejemplares similares
-
Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8(+) T Cells in Non-Melanoma Cancers Compared to Melanoma
por: Gokuldass, Aishwarya, et al.
Publicado: (2020) -
CTLA-4 blockade boosts the expansion of tumor-reactive CD8(+) tumor-infiltrating lymphocytes in ovarian cancer
por: Friese, Christina, et al.
Publicado: (2020) -
Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy
por: Chamberlain, Christopher Aled, et al.
Publicado: (2022) -
Polyfunctional incompletely differentiated CD8+ T cells accumulates after adoptive transfer of tumor-infiltrating lymphocytes and establish immunological memory in patients with metastatic melanoma
por: Donia, Marco, et al.
Publicado: (2015) -
Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy
por: Schina, Aimilia, et al.
Publicado: (2023)